Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven

P Giannakakou1, D L Sackett, Y K Kang

  • 1Medicine Branch, Division of Clinical Sciences, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA.

Insights

Paclitaxel resistance in ovarian cancer cells can stem from tubulin alterations, not P-glycoprotein. Mutations in beta-tubulin residues Phe270 and Ala364 confer paclitaxel resistance by affecting drug interaction with tubulin.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Acquired resistance to paclitaxel, a key chemotherapy drug, is a significant clinical challenge in ovarian cancer treatment.
  • Resistance mechanisms often involve P-glycoprotein efflux or alterations in the target molecule, tubulin.

Purpose of the Study:

  • To investigate novel mechanisms of paclitaxel resistance in human ovarian carcinoma cells.
  • To identify specific molecular changes in tubulin that contribute to paclitaxel resistance.

Main Methods:

  • Development of paclitaxel-resistant sublines (1A9PTX10, 1A9PTX22) from 1A9 human ovarian carcinoma cells.
  • Analysis of drug accumulation, P-glycoprotein expression (MDR-1 mRNA), and tubulin polymerization dynamics.
  • Sequencing of beta-tubulin isotypes to identify mutations.

Main Results:

  • Resistant cells showed no P-glycoprotein involvement and equal drug accumulation but impaired paclitaxel-induced tubulin polymerization.
  • Mutations were identified in the M40 beta-tubulin isotype at Phe270Val (1A9PTX10) and Ala364Thr (1A9PTX22).
  • These mutations altered tubulin's response to paclitaxel but not epothilone B, to which cells remained sensitive.

Conclusions:

  • Paclitaxel resistance in these ovarian cancer sublines is mediated by specific mutations in beta-tubulin.
  • Residues Phe270 and Ala364 are critical for paclitaxel's interaction with tubulin, influencing polymerization and conferring resistance.
  • These findings offer insights into drug resistance mechanisms and potential therapeutic strategies.

Related Concept Videos

Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...